Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1065
Title: Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: the Alfred's experience.
Authors: Wirawan, Jeong
Snell, Greg I.
Levvey, Bronwyn J.
Westall, Glen P.
Morrissey, C. Orla
Ivulich, Steven
Neoh, Chin Fen
Slavin, Monica A.
Kong, David C.M.
Issue Date: 2017
Publication Title: The Journal of Antimicrobial Chemotherapy
Volume: 72
Issue: 7
Start Page: 2089
End Page: 2092
Abstract: This study describes the clinical outcomes and therapeutic drug monitoring (TDM) following posaconazole suspension pre-emptive therapy in lung transplant (LTx) recipients. This was a single-centre, retrospective cohort study evaluating posaconazole suspension pre-emptive therapy in LTx recipients between January 2009 and December 2015. Forty-two LTx recipients were prescribed posaconazole suspension pre-emptively. Aspergillus fumigatus was the most commonly isolated fungal organism. Of the patients receiving posaconazole suspension as the initial antifungal post-LTx, 93% had eradication of colonization at 6 months after commencing therapy. In contrast, only 61% had eradication of fungal colonization when posaconazole suspension was administered following initial therapy with voriconazole. Posaconazole suspension appeared to be well tolerated, although one case was curtailed following concern about abnormal liver function and another due to nausea/vomiting. TDM was performed in 37 patients. The initial median (IQR) trough plasma concentration (Cmin) following 400 mg twice-daily posaconazole suspension was 0.78 (0.46–1.19) mg/L. Doses beyond 800 mg daily did not appear to result in a higher median Cmin Early initiation of posaconazole suspension pre-emptive therapy in LTx recipients appears to be well tolerated and may potentially afford favourable clinical outcomes.
URI: http://hdl.handle.net/11054/1065
DOI: doi.org/10.1093/jac/dkx085
Internal ID Number: 01051
Health Subject: ANTIFUNGAL AGENTS
ASPERGILLUS FUMIGATUS
DRUG MONITORING
LUNG TRANSPLANTATION
POSACONAZOLE
RETROSPECTIVE STUDIES
SUSPENSION
VORICONAZOLE
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.